Ophthalmic Bevacizumab Reaches Critical Review Stage In EU

The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.

3D illustration of BEVACIZUMAB title on a medical document
The EMA is reviewing a marketing application for an ophthalmic formulation of bevacizumab • Source: Alamy

More from Review Pathways

More from Pathways & Standards